Drug Profile
Research programme: LRRK2 protein inhibitors - Parkinson's Institute and Clinical Center/ Merck & Co
Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Merck & Co; Parkinsons Institute and Clinical Center
- Class Antiparkinsonians
- Mechanism of Action LRRK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
- 05 Feb 2018 Parkinson’s Institute and Clinical Center enters into a collaboration with Merck and Co to evaluate LRRK2 protein inhibitors for Parkinson's disease
- 05 Feb 2018 Preclinical trials in Parkinson's disease in USA (unspecified route)